Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate

Blood

Volumn 93, Issue 11, 1999, Pages 3678-3684

  Sievers, E L ^a   Appelbaum, F R ^b   Spielberger, R T ^b   Forman, S J ^b   Flowers, D ^b   Smith, F O ^b   Shannon Dorcy, K ^b   Berger, M S ^b   Bernstein, I D ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CALICHEAMICIN DERIVATIVE; CD33 ANTIGEN; GEMTUZUMAB OZOGAMICIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0033151526     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.11.3678.411k24_3678_3684     Document Type: Article

References (20)

1. Andrews RG, Torok-Storb B, Bernstein ID: Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 62:124, 1983
2. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF: A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 8:521, 1984
3. Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID: Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67:1048, 1986
4. Andrews R, Singer J, Bernstein I: Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med 169:1721, 1989
5. Bernstein ID, Singer JW, Andrews RG, Keating A, Powell JS, Bjornson BH, Cuttner J, Najfeld V, Reaman G, Raskind W, Sutton DMC, Fialkow PJ: Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J Clin Invest 79:1153, 1987
6. Bernstein ID, Singer JW, Smith FO, Andrews RG, Flowers DA, Petersens J, Steinmann L, Najfeld V, Savage D, Fruchtman S, Arlin Z, Fialkow PJ: Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Blood 79:1811, 1992
7. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee TS, Larson SM, Oettgen HF, Old LJ: A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9:478, 1991
8. Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW, Martin PJ, Fisher DR, Nelp WB, Thomas ED, Bernstein ID: The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 54:829, 1992
9. van der Jagt RH, Badger CC, Appelbaum FR, Press OW, Matthews DC, Eary JF, Krohn KA, Bernstein ID: Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res 52:89, 1992
10. Zein N, Sinha AM, McGahren WJ, Ellestad GA: Calicheamicin gamma II: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240:1198, 1988
11. Leith CP, Chen IM, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL: Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux-cases. Blood 86:2329, 1995
12. Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID, Dow LW, Najfeld V, Veith R: Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med 317:468, 1987
13. Mehrotra B, George TI, Kavanau K, Avet-Loiseau H, Moore Dn, Willman CL, Slovak ML, Atwater S, Head DR, Pallavicini MG: Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia. Blood 86:1139, 1995
14. Haase D, Feuring-Buske M, Konemann S, Fonatsch C, Troff C, Verbeek W, Pekrun A, Hiddemann W, Wormann B: Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood 86:2906, 1995
15. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Med 3:730, 1997
16. Niederwieser DW, Appelbaum FR, Gastl G, Gersdorf E, Meister B, Geissler D, Tratkiewicz JA, Thaler J, Huber C: Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med 322:1794, 1990
17. Sievers EL, Larson RA, Estey E, Stadmauer E, Berger M, Eten C, Bernstein I, Appelbaum F: Interim analysis of the efficacy and safety of CMA-676 in patients with AML in first relapse. Blood 92:613a, 1998 (suppl)
18. Jurcic JG, DeBlasio A, Dumont L, Warrell RP Jr, Scheinberg DA: Molecular remission induction without relapse after anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia (APL). Blood 90:416a, 1997 (suppl)
19. Caron PC, Dumont L, Scheinberg DA: Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res 4:1421, 1998
20. Robertson MJ, Soiffer RJ, Freedman AS, Rabinowe SL, Anderson KC, Ervin TJ, Murray C, Dear K, Griffin JD, Nadler LM, Ritz J: Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 79:2229, 1992